Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 8/20 | 0.46 |
| ▸ | NAMPT | P43490 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | LIPE | Q05469 | 1/20 | 0.40 |
| ▸ | ACACB | O00763 | 1/20 | 0.38 |
| ▸ | TACR3 | P29371 | 1/20 | 0.38 |
| ▸ | MMP1 | P03956 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12367663 | 0.82 | OPRK1 (0.42) | HRH3NAMPTKDM4ELIPEALDH1A1 | |
| SCHEMBL30222191 | 0.81 | ALDH1A1 (0.49) | HRH3NAMPTKDM4EALDH1A1L3MBTL1 | |
| SCHEMBL23147699 | 0.81 | ALDH1A1 (0.49) | HRH3NAMPTKDM4EALDH1A1L3MBTL1 | |
| SCHEMBL12367671 | 0.80 | HRH3 (0.46) | HRH3NAMPTLIPEACACBMEN1 | |
| SCHEMBL17976902 | 0.78 | RAB9A (0.52) | HRH3KDM4EMEN1KMT2AALDH1A1 | |
| SCHEMBL15571936 | 0.78 | RAB9A (0.52) | HRH3KDM4EMEN1KMT2AALDH1A1 | |
| SCHEMBL2004014 | 0.78 | HRH3 (0.58) | HRH3KCNH2 | |
| SCHEMBL2893597 | 0.78 | ALDH1A1 (0.46) | HRH3NAMPTKDM4EACACBALDH1A1 | |
| SCHEMBL13003322 | 0.78 | LIPE (0.42) | HRH3NAMPTKDM4ELIPEALDH1A1 | |
| SCHEMBL16702162 | 0.77 | NAMPT (0.45) | NAMPTLIPEGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110207734-A1 | Azine Derivatives and Methods of Use Thereof | PALANI ANANDAN | 2011-08-25 | — | — | US | disclosed |
| US-20110207734-A1 | Azine Derivatives and Methods of Use Thereof | PALANI ANANDAN | 2011-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110207734-A1 | Azine Derivatives and Methods of Use Thereof | AZI2, GPR119, GID4 | HRH3 335/4885NAMPT 2261/4885KDM4E 1411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.